Turkish Society of Hematology Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial
2006
NCT00934154
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2011

Timeline

NOW
  • Now

Alternative names

Turkish Society of Hematology Myeloma Study Group

Active Ingredients

Drugs in Phase 4 Trials (1)

atorvastatin (lipitor) (1 trial)

Drugs in Phase 3 Trials (3)

melphalan (alkeran) (1 trial)

prednisone (meticorten) (1 trial)

thalidomide (Thalomid) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Myeloma (Phase 3)

Neoplasms, Plasma Cell (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 2
  • # of Trial APIs: 4